



September 27, 2017

## Vericel to Present at the 2017 Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the Cell & Gene Meeting on the Mesa at the Estancia La Jolla Hotel & Spa in La Jolla, CA on Wednesday, October 4, 2017 at 5:45pm PDT.

Mr. Colangelo will also participate in the plenary session "Implications of Commercialization: What Does Approval Mean?" at 9:15am PDT.

Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts: the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium.

A live video webcast of all company presentations will be available at <http://www.meetingonthemesa.com/webcast> and will also be published on ARM's website shortly after the event.

### About Vericel Corporation

Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI<sup>®</sup> (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel<sup>®</sup> (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at [www.vcel.com](http://www.vcel.com).

Epicel<sup>®</sup> and MACI<sup>®</sup> are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.

### Global Media Contacts:

David Schull  
Russo Partners LLC  
+1 212-845-4271 (office)  
+1 858-717-2310 (mobile)  
David.schull@russopartnersllc.com

Karen Chase  
Russo Partners LLC  
+1 646-942-5627 (office)  
+1 917-547-0434 (mobile)  
Karen.chase@russopartnersllc.com

### Investor Contacts:

Chad Rubin  
The Trout Group  
crubin@troutgroup.com  
+1 (646) 378-2947

Lee Stern  
The Trout Group  
lstern@troutgroup.com  
+1 (646) 378-2922